Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2012

View Archived Issues

Roche reflects on accomplishments of second quarter 2012

Sirolimus reduces skin cancer occurrence in renal transplant recipients

Pol I inhibitor shows anticancer potency in vitro and in vivo

MEK inhibitor improves survival in METRIC trial

Kyowa Hakko Kirin presents overview of first half 2012

Researchers at Novartis disclose novel beta-secretase inhibitors

Sanofi updates R&D progress of second quarter 2012

New sodium channel blockers designed by Pfizer

Korean group prepares new GPR119 receptor ligands

Bionor Pharma presents new candidate vaccines

Belgian scientists divulge novel antiviral alphabodies

Beta Pharma patents novel protein kinase inhibitors

GSK confirms submissions for dabrafenib and trametinib

New technique offers alternative to gene therapy

Zaltrap approved in U.S. for cancer indication

ACT advances stem cell trial for dry AMD

FDA assigns PDUFA action date for enzalutamide NDA

Ono kicks off first-in-human study of peptide-cocktail vaccine

Pluristem reports second successful compassionate use of PLX cells

Daiichi Sankyo presents overview of first quarter fiscal 2012

UCB reviews events of first half 2012

U.S. university and Novartis form global alliance for anticancer T-cell immunotherapies

NIH awards grant to support study of Immuron candidate drug for steatohepatitis

Marina Biotech grants Novartis license for CRN technology